Nuvation Bio is a clinical-stage biopharmaceutical company developing therapeutic candidates focused on treating patients with cancers. Co. is developing six wholly owned compounds that have resulted from its drug discovery and development programs, which include: NUV-422, a selective small molecule inhibitor of cyclin-dependent kinase; NUV-868, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor; NUV-569, an oral small molecule selective inhibitor of Wee1 kinase, a regulator of DNA damage repair; and a drug-drug conjugate platform, which is a therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates. The NUVB stock yearly return is shown above.
The yearly return on the NUVB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NUVB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|